FDA gives clearance to commence Ph 2 trial of leronlimab in patients with R/R MSS CRC November 13, 2024
Ph 1b Clinical Trial expanded to Evaluate TTX-080 in Combination with Cetuximab and Chemotherapy in Advanced Colorectal Cancer November 5, 2024
FDA clearance to commence Ph 2 trial of leronlimab in patients with R/R microsatellite stable CRC November 5, 2024
Interim Ph 2 Data for GRANITE Neoantigen Targeting Immunotherapy in 1L Metastatic MSS CRC Announced October 8, 2024
Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer October 2, 2024
FAILED TRIAL: Ph 3 KEYFORM-007 trial of favezelimab + KEYTRUDA did not meet its primary endpoint of OS in patients with previously treated PD-L1+ve MSS mCRC October 1, 2024
FRUZAQLA (fruquintinib) approved in Japan for the Treatment of Unresectable Advanced or Recurrent CRC October 1, 2024
FAILED TRIAL: CONTACT-02 Ph 3 mCRC trial did not meet statistical significance of OS endpoint September 17, 2024
FAILED TRIAL: Ph 2 NuTide:323 CRC Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee September 3, 2024
End-of-Phase-2 Meeting Outcomes and Topline Interim Ph 2 Data for BOT/BAL in MSS Colorectal Cancer announced July 23, 2024
Positive Initial Data Announced from Ph 1 MINOTAUR Trial of Lunresertib in Combination with FOLFIRI July 1, 2024
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial June 25, 2024
EU approves FRUZAQLA in Previously Treated Metastatic Colorectal Cancer Based on Results from Ph 3 FRESCO-2 Trial June 25, 2024
FDA grants Accelerated Approval to KRAZATI® (adagrasib) + Cetuximab for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic CRC June 25, 2024
First Patient Dosed in trial Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC June 3, 2024
First Patient Dosed in Randomized Ph 2 Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy May 29, 2024
China CDE Clearance for Ph 3 Trial of KRAS G12C Inhibitor Glecirasib in Patients with CRC Announced May 21, 2024
FDA Grants Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for R/R Metastatic CRC May 21, 2024
FDA Approves GFH925 (KRAS G12C Inhibitor) Monotherapy trial in Ph 3 Registrational Study Treating Metastatic CRC May 1, 2024
